Moreover, the pharmacological inhibition of SPHK1 or the functional antagonism of S1PR1 disrupted fibrocyte trafficking, reduced extracellular matrix deposition, and ameliorated lung fibrosis, underscoring the therapeutic potential of targeting this pathway. Here, S1PR1 is linked to pulmonary fibrosis.